Abstract
The third version of the Japan Society of Gynecologic Oncology guidelines for the treatment of uterine body neoplasms was published in 2013. The guidelines comprise nine chapters and nine algorithms. Each chapter includes a clinical question, recommendations, background, objectives, explanations, and references. This revision was intended to collect up-to-date international evidence. The highlights of this revision are to (1) newly specify costs and conflicts of interest; (2) describe the clinical significance of pelvic lymph node dissection and para-aortic lymphadenectomy, including variant histologic types; (3) describe more clearly the indications for laparoscopic surgery as the standard treatment; (4) provide guidelines for post-treatment hormone replacement therapy; (5) clearly differentiate treatment of advanced or recurrent cancer between the initial treatment and the treatment carried out after the primary operation; (6) collectively describe fertility-sparing therapy for both atypical endometrial hyperplasia and endometrioid adenocarcinoma (corresponding to G1) and newly describe relapse therapy after fertility-preserving treatment; and (7) newly describe the treatment of trophoblastic disease. Overall, the objective of these guidelines is to clearly delineate the standard of care for uterine body neoplasms in Japan with the goal of ensuring a high standard of care for all Japanese women diagnosed with uterine body neoplasms.
This is a preview of subscription content, log in via an institution to check access.
Access this article
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Similar content being viewed by others
References
Matsuda A, Matsuda T, Shibata A et al (2014) Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 44(4):388–396
For act on anti-cancer measures based on the data of statistics white paper 2012 (Shinoharashinsha Publishers Inc.) Cancer Information Service, National Cancer Center, Japan
Nagase S, Katabuchi H, Hiura M et al (2010) Evidence-based guidelines for treatment of uterine body neoplasmin Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition. Int J Clin Oncol 15:531–542
Ariyoshi H (2002) Guideline for correct use of antineoplastic agents (draft). General theory. Gan To Kagaku Ryoho 29(6):970–977 (in Japanese)
Ochiai K, Okamoto A, Katsumata N (2002) Guidelines for proper use of antineoplastic agents. Gynecologic cancer. Gan To Kagaku Ryoho 29(6):1047–1054 (in Japanese)
Fukui T, Yoshida M, Yamaguchi N (2007) Minds clinical practice guideline. Igaku-Shoin, Tokyo, p 40 (in Japanese)
Dowdy SC, Mariani A, Lurain JR (2012) Uterine cancer. In: Berek JS (ed) Berek and Novak’s gynecology, 15th edn. Lippincot Williams & Wilkins, Philadelphia, PA, pp 1250−1303
Miller DS, Creasman WT (2012) Adenocarcinoma of the uterine corpus. In: DiSaia PJ, Creasman WT (eds) Clinical gynecologic oncology, 8th edn. Elsevier Saunders, Philadelphia, pp 141–174
Acknowledgments
We thank the Japan Society of Obstetrics and Gynecology, the Japan Association of Obstetricians and Gynecologists, the Japanese Gynecologic Oncology Group, the Japan Society of Clinical Oncology, and the Japanese Society for Therapeutic Radiology and Oncology for their comments and contributions throughout the project. We also acknowledge the support by grants from the Ministry of Health, Labour and Welfare and H24-Clinical Cancer Research-001 (chief researcher, Koichi Hirata).
Members of guidelines formulation committee Yasuhiko Ebina, Hisaya Fujiwara, Shinji Fukunaga, Yasuyuki Hasuo, Atsushi Hongo, Kazuhiko Ino, Yuko Kaneyasu, Hidenori Kato, Naoki Kawamura, Yoichi Kobayashi, Kaneyuki Kubushiro, Masataka Kudo, Hideo Matsui, Koji Matsumoto, Yoshiki Mikami, Toshinari Muramatsu, Shoji Nagao, Satoru Nagase, Takafumi Nakamura, Toru Nakanishi, Satoru Nakayama, Hideyuki Ohtake, Yoshikazu Ozaki, Nobuyuki Susumu, Tsutomu Tabata, Kiyoshi Takamatsu, Masashi Takano, Satoshi Takeuchi, Yoshito Terai, Takafumi Toita, Akiko Tozawa, Takashi Uno, Hidemichi Watari, Tetsuro Yahata, Hideko Yamamoto, Koji Yamazawa, Nozomu Yanaihara, Masami Yasuda, Yoshihito Yokoyama.
Members of guidelines evaluation committee Daisuke Aoki, Yoichi Aoki, Makoto Emoto, Takayuki Enomoto, Toru Hachisuga, Seiryu Kamoi, Takahiro Kasamatsu, Noriyuki Katsumata, Junzo Kigawa, Hiroaki Kobayashi, Takeshi Kodaira, Junichi Kodama, Shinichi Komiyama, Hiroyuki Kuramoto, Makoto Kuroda, Masaki Mandai, Etsuko Miyagi, Takashi Nakano, Kaei Nasu, Fumitaka Numa, Kazunori Ochiai, Tsuyoshi Saito, Toshiaki Saito, Masaru Sakamoto, Noriaki Sakuragi, Nobuhiro Takeshima, Toshimitsu Toya, Satoshi Umezawa, Yoh Watanabe, Hiroyuki Yanai.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Kiyoshi Takamatsu received lecture fees from Bayer Yakuhin, Ldt, and Pfizer Japan Inc.
Additional information
This article originally appeared in Japanese as Shikyu taigan chiryo gaidorain 2013 nen ban, published by Kanehara, Tokyo, 2013.
About this article
Cite this article
Ebina, Y., Katabuchi, H., Mikami, M. et al. Japan Society of Gynecologic Oncology guidelines 2013 for the treatment of uterine body neoplasms. Int J Clin Oncol 21, 419–434 (2016). https://doi.org/10.1007/s10147-016-0981-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-016-0981-1